14 February 2019

UCLB, the wholly owned subsidiary technology commercialisation company of UCL, has appointed Dr Anne Lane as its new Managing Director.

As part of UCL Innovation & Enterprise, and a leading university technology transfer business in the UK and globally, UCLB has a track record of supporting the commercialisation of technologies developed in UCL.

Since joining UCL in 2000, Anne has been instrumental in building UCLB’s foundations, and through various roles in the company has guided some of the university’s most outstanding successes, in particular Stanmore Implants, Apollo Therapeutics, the UCL Technology Fund and Orchard Therapeutics.

Welcoming Anne to her new role, UCL’s Vice-Provost (Enterprise) Dr Celia Caulcott, said:

“Through her extensive knowledge and experience of UCL and its partner hospitals, Anne will make a tremendous contribution to the future success of UCLB, building on its current successes and spearheading new ventures. In addition, as a member of the UCL Innovation & Enterprise Directors team, her experience, skills and knowledge will contribute to the wider innovation and enterprise agenda at UCL, and thus to the future success of the university.

“I very much look forward to working with Anne, and know that you will all welcome her as she joins us in her new role.”

Anne has a PhD in medicine from UCL and an Executive MBA from Molson Business School, Montreal. After research at UCL and teaching and research at Harvard University and Harvard Medical School, Anne worked for RTP Pharma Inc in Montreal, out-licensing and preparing valuations of the company’s portfolio for public listing. Anne joined UCL Ventures in 2000 and acted as consultant for the National Transfer Centre in the US.

On learning of her appointment Anne said: “I’m thrilled at this opportunity to lead UCLB, and continue our mission to translate knowledge and discoveries for the benefit of wider society and the economy. UCL is an incredible community of thinkers and innovators and UCLB is in an excellent position to support the commercialisation of technologies developed in UCL, alongside the many routes for research transfer and knowledge exchange that UCL Innovation & Enterprise supports.”

Anne will take up her role from 1st March 2019.